近红外光免疫治疗肿瘤细胞毒性机制研究

Kazuhide Sato
{"title":"近红外光免疫治疗肿瘤细胞毒性机制研究","authors":"Kazuhide Sato","doi":"10.2530/jslsm.jslsm-41_0020","DOIUrl":null,"url":null,"abstract":"Near-infrared photoimmunotherapy (NIR-PIT) is a recently developed next-generation cancer photo-target therapy that combines the specificity of intravenously injected antibodies for targeting tumors with toxicity induced by photoabsorber (IR700) after exposure to NIR-light. NIR-PIT is realized its multidisciplinary method with the combination of the technologies in chemistry, biolody, pharmacology and physics. Presently, NIR-PIT is under the international phase III clinical trial against locoregional, recurrent head and neck SCC (HNSCC) (LUZERA-301, NCT03769506) with FDA fast track approval and expected to be clinically licensed in a few years. However, the precise mechanism of NIR-PIT is still unknown. In this review, the scheme of NIR-PIT and the mechanism of NIR-PIT is outlined.","PeriodicalId":19350,"journal":{"name":"Nippon Laser Igakkaishi","volume":"32 1","pages":"104-109"},"PeriodicalIF":0.0000,"publicationDate":"2020-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"A Mechanism of Cancer Cell Cytotoxicity of Near-Infrared Photoimmunotherapy\",\"authors\":\"Kazuhide Sato\",\"doi\":\"10.2530/jslsm.jslsm-41_0020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Near-infrared photoimmunotherapy (NIR-PIT) is a recently developed next-generation cancer photo-target therapy that combines the specificity of intravenously injected antibodies for targeting tumors with toxicity induced by photoabsorber (IR700) after exposure to NIR-light. NIR-PIT is realized its multidisciplinary method with the combination of the technologies in chemistry, biolody, pharmacology and physics. Presently, NIR-PIT is under the international phase III clinical trial against locoregional, recurrent head and neck SCC (HNSCC) (LUZERA-301, NCT03769506) with FDA fast track approval and expected to be clinically licensed in a few years. However, the precise mechanism of NIR-PIT is still unknown. In this review, the scheme of NIR-PIT and the mechanism of NIR-PIT is outlined.\",\"PeriodicalId\":19350,\"journal\":{\"name\":\"Nippon Laser Igakkaishi\",\"volume\":\"32 1\",\"pages\":\"104-109\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-07-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nippon Laser Igakkaishi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2530/jslsm.jslsm-41_0020\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nippon Laser Igakkaishi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2530/jslsm.jslsm-41_0020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

近红外光免疫疗法(NIR-PIT)是一种新发展的新一代癌症光靶向疗法,它结合了静脉注射抗体靶向肿瘤的特异性和暴露于nir光吸收剂(IR700)后引起的毒性。NIR-PIT采用化学、生物学、药理学和物理学等多学科技术相结合的方法来实现。目前,nil - pit正在进行针对局部区域复发性头颈部鳞状细胞癌(HNSCC)的国际III期临床试验(LUZERA-301, NCT03769506),并已获得FDA快速通道批准,预计将在几年内获得临床许可。然而,NIR-PIT的确切机制尚不清楚。本文综述了NIR-PIT的方案和NIR-PIT的机理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Mechanism of Cancer Cell Cytotoxicity of Near-Infrared Photoimmunotherapy
Near-infrared photoimmunotherapy (NIR-PIT) is a recently developed next-generation cancer photo-target therapy that combines the specificity of intravenously injected antibodies for targeting tumors with toxicity induced by photoabsorber (IR700) after exposure to NIR-light. NIR-PIT is realized its multidisciplinary method with the combination of the technologies in chemistry, biolody, pharmacology and physics. Presently, NIR-PIT is under the international phase III clinical trial against locoregional, recurrent head and neck SCC (HNSCC) (LUZERA-301, NCT03769506) with FDA fast track approval and expected to be clinically licensed in a few years. However, the precise mechanism of NIR-PIT is still unknown. In this review, the scheme of NIR-PIT and the mechanism of NIR-PIT is outlined.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信